Medical device degradation products evaluation is a critical component of biological safety assessment, required to identify and quantify the chemical compounds released when polymeric, metallic, and ceramic materials break down inside the body. This article provides a comprehensive technical overview of the evaluation framework defined by the ISO 10993 series, covering testing samples, analytical items, laboratory methods, regulatory applications, and frequently asked questions.
Technical Overview
Degradation products are chemical species generated when a medical device material decomposes under physiological conditions through processes such as hydrolysis, oxidation, enzymatic attack, corrosion, or mechanical wear. Unlike extractables and leachables, which migrate from an intact material, degradation products are newly formed compounds that appear only after the material structure itself has broken down. Because these substances can be chemically distinct from the base material and can accumulate in tissues, regulatory authorities worldwide require a science-based degradation assessment for devices with resorbable components or long-term body contact.
The evaluation framework is defined primarily by the ISO 10993 series of standards:
- ISO 10993-9 establishes the general framework for the identification and quantification of potential degradation products within a risk management process aligned with ISO 10993-1.
- ISO 10993-13 specifies test methods for polymeric medical devices, including accelerated and real-time degradation studies.
- ISO 10993-14 addresses degradation products from ceramics, including dissolution testing at physiological and extreme pH values.
- ISO 10993-15 covers degradation products from metals and alloys, combining immersion testing with electrochemical corrosion assessment.
- ISO 10993-17 and ISO 10993-18 support the toxicological risk assessment and chemical characterization needed to interpret degradation data.
When degradation is expected or demonstrated, the identified products must be quantified, compared against allowable exposure limits, and integrated into the overall biological risk assessment file submitted to regulators such as the FDA, notified bodies under the EU MDR, and the NMPA.
Testing Samples
Polymeric Materials and Devices
Polymeric samples include bioresorbable polymers such as polylactic acid (PLA), poly(lactic-co-glycolic acid) (PLGA), polycaprolactone (PCL), polydioxanone, as well as non-resorbable polymers used in long-term implants such as polyethylene, polyurethane, silicone elastomers, and acrylic adhesives. Both injection-molded coupons and finished device configurations (screws, scaffolds, films, meshes) can be evaluated per ISO 10993-13.
Metallic Materials and Implants
Metallic samples cover titanium and titanium alloys, cobalt-chromium alloys, stainless steels, nitinol, and bioabsorbable magnesium- and zinc-based alloys. Testing per ISO 10993-15 targets ion release (such as cobalt, chromium, nickel, vanadium, aluminum, and magnesium), surface corrosion morphology, and electrochemical behavior.
Ceramic and Inorganic Materials
Ceramic samples include hydroxyapatite, beta-tricalcium phosphate, bioactive glasses, aluminum oxide, and zirconium oxide used in orthopedic and dental applications. Dissolution testing per ISO 10993-14 quantifies released ionic species such as calcium, phosphate, silicate, and trace metal impurities.
Finished Devices and Material Coupons
Representative samples of the final device, in its sterilized and final packaged condition, are preferred whenever possible because processing, sterilization, and surface treatment significantly influence degradation behavior. Where finished devices cannot be sacrificed for testing, standardized material coupons of identical composition and surface finish may be used with scientific justification.
Testing Items
A typical degradation products evaluation program includes the following test items:
- Identification of degradation products: monomers, oligomers, hydrolysis fragments, oxidation products, metal ions, and ceramic dissolution species.
- Quantification of each detected degradation product against analytical reference standards.
- Mass change and mass loss determination over defined exposure intervals.
- Molecular weight characterization of polymeric samples by gel permeation chromatography (GPC) to track chain scission.
- Solution pH and osmolality monitoring of the degradation medium.
- Surface analysis by scanning electron microscopy (SEM), energy-dispersive X-ray spectroscopy (EDS), Fourier-transform infrared spectroscopy (FTIR), and X-ray photoelectron spectroscopy (XPS).
- Mechanical property retention testing, such as tensile strength, flexural strength, or crush resistance, at each time point.
- Corrosion parameters for metals, including open circuit potential, breakdown potential, and repassivation potential per ASTM F2129.
- Degradation kinetics modeling to estimate product release rates over the intended clinical lifetime.
- Toxicological screening of identified products against safety thresholds derived from ISO 10993-17 or recognized toxicological reference values.
Testing Methods
Testing is performed under two complementary approaches. Real-time degradation uses physiologically relevant conditions over the actual or extrapolated device lifetime, while accelerated degradation applies elevated temperatures or chemically aggressive media to shorten the study timeline, with results validated against real-time reference data. Temperature selection and extrapolation logic follow the principles of ASTM F1980 and the material-specific requirements of the ISO 10993 degradation parts.
Common analytical techniques and their roles include:
- High-performance liquid chromatography (HPLC) and LC-MS/MS for separating and identifying oligomeric and monomeric degradation products of resorbable polymers.
- Gas chromatography-mass spectrometry (GC-MS) for volatile and thermally stable organic fragments.
- Gel permeation chromatography (GPC/SEC) for molecular weight distribution and polydispersity tracking.
- Inductively coupled plasma mass spectrometry (ICP-MS) and ICP-OES for trace-level quantification of released metal ions and ceramic elements.
- Ion chromatography for inorganic anions such as phosphate and silicate.
- NMR spectroscopy for structural confirmation of polymer degradation fragments.
- SEM/EDS and XPS for surface morphology, pitting, and passivation layer characterization.
- Electrochemical methods, including cyclic potentiodynamic polarization per ASTM F2129, for metallic corrosion susceptibility.
- Immersion testing in simulated body fluids such as phosphate-buffered saline or Hanks' balanced salt solution, with extreme-pH solutions used for ceramics per ISO 10993-14.
Test protocols specify sample geometry, surface-area-to-solution-volume ratios, time points, temperature, media renewal schedules, and analytical recovery validation to ensure reproducible and regulatorily acceptable data. All studies should be conducted in ISO/IEC 17025-accredited third-party laboratories or equivalently qualified facilities.
Applications
Degradation products evaluation supports a broad range of device categories and development activities:
- Bioresorbable orthopedic implants, including interference screws, plates, pins, and suture anchors made from PLA or PLGA.
- Bioabsorbable cardiovascular devices such as drug-eluting and fully resorbable scaffolds and magnesium-based stents.
- Tissue engineering scaffolds and guided regeneration membranes in dental and maxillofacial applications.
- Long-term permanent implants, including joint replacement bearings, spinal implants, pacemaker leads, and cardiac valves, where corrosion and wear particle generation must be characterized.
- Regulatory submissions, including FDA 510(k) and PMA packages, EU MDR technical documentation, and NMPA registration dossiers, where degradation data underpin the biological safety evaluation.
- Research and development activities such as material screening, formulation comparison, sterilization impact studies, and shelf-life or stability programs.
- Post-market surveillance and change control when materials, suppliers, or manufacturing processes are modified.
FAQ
When is a degradation products study required?
A study is generally required when the device, or any component, is intended to remain in contact with body tissues for more than 30 days, when the material is designed to be resorbable, or when chemical breakdown is plausible under clinical use. ISO 10993-1 and ISO 10993-9 require the degradation assessment to be documented in the biological risk management file even when a full study is ultimately waived with justification.
What is the difference between degradation products and extractables or leachables?
Extractables and leachables are substances that migrate out of an intact material, such as residual monomers, additives, and processing aids. Degradation products are new chemical entities formed only when the material structure decomposes. A complete chemical safety evaluation per ISO 10993-18 and ISO 10993-9 addresses both categories, and some compounds may appear in both data sets.
Which standard applies to my material?
Use ISO 10993-13 for polymers, ISO 10993-14 for ceramics, and ISO 10993-15 for metals and alloys, always within the overall framework of ISO 10993-9. Composite devices containing multiple material classes require testing against each applicable part or a documented rationale for the testing strategy.
Can accelerated testing replace real-time testing?
Accelerated testing is useful for screening and early development decisions, but it cannot fully replace real-time data for regulatory submission of resorbable devices. Regulators typically expect concurrent real-time studies running in parallel, with accelerated results supported by Arrhenius-based extrapolation and verified against real-time reference points.
How are degradation data used in the safety assessment?
Identified degradation products are quantified, converted into patient exposure estimates based on device use conditions, and compared with allowable limits derived from ISO 10993-17, toxicological thresholds of concern, or compound-specific toxicological profiles. Products exceeding safety margins trigger additional risk mitigation, formulation changes, or extended toxicological evaluation.
How long does a degradation study take?
Real-time studies for bioresorbable polymers often extend from several months to more than two years to cover the full resorption profile, while metallic and ceramic immersion studies may be completed in weeks to months depending on the intended contact duration. Study design should be finalized with the testing laboratory and, where possible, pre-aligned with the expectations of the target regulatory market.